Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

NCT03697109 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT03697109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2018
Completion date
April 15, 2024
Enrollment
152 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

cushing syndrome